Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 1
1965 1
1967 2
1969 4
1970 1
1971 5
1975 1
1976 4
1979 2
1980 1
1981 2
1982 1
1983 2
1984 2
1985 1
1986 4
1987 4
1988 4
1989 3
1990 1
1991 4
1992 2
1993 3
1995 4
1996 6
1997 3
1998 10
1999 7
2000 12
2001 9
2002 17
2003 14
2004 14
2005 16
2006 15
2007 14
2008 9
2009 10
2010 12
2011 14
2012 22
2013 21
2014 26
2015 30
2016 28
2017 23
2018 29
2019 34
2020 25
2021 41
2022 38
2023 14

Text availability

Article attribute

Article type

Publication date

Search Results

517 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic options in thymomas and thymic carcinomas.
Muto Y, Okuma Y. Muto Y, et al. Among authors: okuma y. Expert Rev Anticancer Ther. 2022 Apr;22(4):401-413. doi: 10.1080/14737140.2022.2052278. Epub 2022 Apr 4. Expert Rev Anticancer Ther. 2022. PMID: 35266421 Review.
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
Higashiyama RI, Yoshida T, Yagishita S, Ohuchi M, Sakiyama N, Torasawa M, Shirasawa M, Masuda K, Shinno Y, Matsumoto Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Hamada A, Ohe Y. Higashiyama RI, et al. Among authors: okuma y. J Thorac Oncol. 2022 Oct;17(10):1227-1232. doi: 10.1016/j.jtho.2022.06.010. Epub 2022 Jul 3. J Thorac Oncol. 2022. PMID: 35788404
Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
Shinno Y, Yoshida A, Masuda K, Matsumoto Y, Okuma Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Yatabe Y, Ohe Y. Shinno Y, et al. Among authors: okuma y. Clin Lung Cancer. 2022 Jul;23(5):386-392. doi: 10.1016/j.cllc.2022.03.005. Epub 2022 Apr 29. Clin Lung Cancer. 2022. PMID: 35618627
Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
Shirasawa M, Yoshida T, Shimoda Y, Takayanagi D, Shiraishi K, Kubo T, Mitani S, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Ichikawa H, Kohno T, Yamamoto N, Matsumoto S, Goto K, Watanabe SI, Ohe Y, Motoi N. Shirasawa M, et al. Among authors: okuma y. J Thorac Oncol. 2021 Dec;16(12):2078-2090. doi: 10.1016/j.jtho.2021.07.027. Epub 2021 Aug 20. J Thorac Oncol. 2021. PMID: 34419685 Free article.
Unarranged territory in uncommon EGFR mutations.
Fujii H, Okuma Y. Fujii H, et al. Among authors: okuma y. Transl Lung Cancer Res. 2022 Jul;11(7):1233-1236. doi: 10.21037/tlcr-22-478. Transl Lung Cancer Res. 2022. PMID: 35958324 Free PMC article. No abstract available.
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A; KAICA trial Investigators. Hamada H, et al. Among authors: okuma y. Lancet. 2019 Mar 16;393(10176):1128-1137. doi: 10.1016/S0140-6736(18)32003-8. Epub 2019 Mar 7. Lancet. 2019. PMID: 30853151 Clinical Trial.
517 results